Javier Pérez Stachowski

ORCID: 0000-0002-5189-1953
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • Cytomegalovirus and herpesvirus research
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Cerebral Venous Sinus Thrombosis
  • Hepatitis B Virus Studies
  • Tuberculosis Research and Epidemiology
  • Retinal and Optic Conditions
  • Liver Disease and Transplantation
  • HIV/AIDS oral health manifestations
  • Mobile Health and mHealth Applications
  • Neurogenetic and Muscular Disorders Research
  • Renal Transplantation Outcomes and Treatments
  • Parkinson's Disease Mechanisms and Treatments
  • Autoimmune and Inflammatory Disorders Research
  • HIV, Drug Use, Sexual Risk
  • Fungal Infections and Studies
  • Public Health and Environmental Issues
  • Amyotrophic Lateral Sclerosis Research

Hospital Costa del Sol
2015-2024

Hospital Universitario Ramón y Cajal
2020

Instituto Ramón y Cajal de Investigación Sanitaria
2020

Universidad de Alcalá
2020

Sergio Serrano‐Villar Javier Martínez‐Sanz Raquel Ron Alba Talavera-Rodríguez Borja M. Fernández-Félix and 95 more Sabina Herrera Alfonso Muriel Francisco Fanjul Joaquín Portilla Josefa Muñoz Concha Amador Miguel Alberto de Zárraga María Jesús Vivancos Santiago Moreno Inmaculada Jarrín Santiago Moreno Belén Alejos María Ángeles Muñoz‐Fernández Irene Consuegra Esperanza Merino Gema García Ana López Lirola Dácil García Víctor Asensi Eulalia Valle-Garay Rafael Rubio Federico Pulido José Antonio Iribarren Julio Arrizabalaga Félix Gutiérrez Mar Masiá Roberto Muga Arantza Sanvisens Juan Berenguer Francesc Vidal Marta Montero José Ramón Blanco Juan Carlos López Bernarlo de Quirós Juan González‐García Joaquín Peraire Piedad Arazo José López‐Aldeguer David Dalmau Francisco Arnalich María Rivero José A. Oteo Gloria Sampériz María José Amengual Ángeles Jaén Ignacio de los Santos Jesús Repáraz Gemma Navarro Enrique Bernal Jesús Sanz Pompeyo Viciana Féderico García José L. Casado Jorge del Romero Alfredo del Caño Antonio Antela José Hernández‐Quero Melchor Riera Montserrat Raposo Jesús Santos Elena Losada Daniel Daniel Podzamczer María Luz Pintos Peñaranda Cristina Gómez Ayerbe Núria Espinosa Julián Olalla Arkaitz Imaz Onofre Juan Martínez Adrián Curran Ángeles Castro Javier Pérez Stachowski Josefa Muñoz Francisco Jesús Vera Carlos Galera Berta Pernas Concha Amador Miren Zuriñe Helena Albendín Inés Suárez‐García Francisco Pasquau Mohamed Omar Eduardo Malmierca Miguel Alberto de Zárraga María Amparo Gómez Vidal Vicente Estrada Miguel Górgolas José Sanz María Jesús Téllez Marı́a José Galindo Alfonso Cabello Antonio Rivero Alberto Arranz Miguel Cervero Ramón Fernando Vilalta Juan A. Pineda

10.1016/s2352-3018(20)30202-2 article EN The Lancet HIV 2020-08-01

Background: New technologies can promote knowledge of HIV infection among patients suffering from this disease. Older with represent an increasingly large group that could benefit the use specific apps. Objective: The aim study was to observe acceptability and a mobile app on in at least 60 years old offer them possibility anonymously establishing contact their peers. Methods: A series clinical psychosocial parameters were studied 30 HIV-infected over years. must be old, follow-up outpatient...

10.2196/mhealth.9904 article EN cc-by JMIR mhealth and uhealth 2018-10-18

In April 2015, the Spanish National Health System (SNHS) developed a national strategic plan for diagnosis, treatment, and management of hepatitis C virus (HCV). Our aim was to analyze impact this on human immunodeficiency (HIV)-infected patients included in HERACLES cohort during first 6 months its implementation. The (NCT02511496) set up March 2015 evaluate status follow-up chronic HCV infection co-infected with HIV south Spain. September data were analyzed identify clinical events (death,...

10.1007/s10096-016-2822-6 article EN cc-by European Journal of Clinical Microbiology & Infectious Diseases 2016-10-27

Generic drugs may help to support antiretroviral treatment. We want assess the efficacy and safety at 24 weeks of change coformulated (abacavir + lamivudine dolutegravir) lamivudine) as a generic pharmaceutical specialty dolutegravir.Between February June 2017, switch from Triumeq® co-formulated tablet plus Tivicay® was made. Demographic, viroimmunological characteristics Charlson index were collected. Six months after switching, evaluated.Switch made in 93 patients, with mean age 47 years,...

10.1186/s40360-018-0252-z article EN cc-by BMC Pharmacology and Toxicology 2018-10-10

Objectives Our objective was to identify patient factors associated with being untreated for hepatitis C virus ( HCV ) infection in HIV ‐coinfected patients. Methods A prospective longitudinal study carried out. ‐infected patients active chronic included the HERACLES cohort NCT 02511496) constituted population. The main outcome receipt of direct‐acting antiviral DAA treatment from 1 May 2015 2017. population divided into who were receiving during follow‐up and those not. Results Of 15 556...

10.1111/hiv.12715 article EN HIV Medicine 2019-04-22

Introduction: Generic drugs are helpful to enhance the efficiency of sanitary system. A generic coformulation abacavir (ABC) and lamivudine (3TC) is available since 2016 in Spain. report our experience with its use exposed.Methods: Patients between February 2017 June who were taking Triumeq® switched ABC + 3TC plus DTG. Efficacy, safety, reasons for discontinuation costs savings evaluated at 48 weeks.Results: Switch was made 93 patients, a median age 47 years mean time 12.33 HIV infection....

10.1080/23744235.2019.1637536 article EN Infectious Diseases 2019-07-05

Objective: The primary endpoint of the study was to determine proportion patients with HIV RNA < 50 copies/mL at 48 weeks. Design: Phase IV, multicentric, open-label, single-arm clinical trial participants recruited in 2018−2019 evaluate efficacy and safety tenofovir alafenamide/emtricitabine/elvitegravir-cobicistat (TAF/FTC/EVG-c) as first-line treatment HIV-1 infected naïve advanced disease. Methods: Adverse events were graded according Division AIDS scale version 2.0. Quantitative...

10.3390/jcm11174994 article EN Journal of Clinical Medicine 2022-08-25

Varón de 52 años que refiere desde hace meses un síndrome constitucional y debilidad en miembros. En sus antecedentes destacaba una ingesta excesiva alcohol. El electroneuromiograma inicial mostró datos sugerentes polineuropatía predominio axonal. estudio con analítica, TC tórax, ecografía abdominal, endoscopia digestiva alta no detectó neoplasia. Durante el seguimiento, a pesar abandonar consumo alcohol, persistió generalizada, amiotrofias progresivas, voz nasal disfagia, destacando la...

10.32818/reccmi.a2n1a8 article ES cc-by-nc-nd Revista Española de Casos Clínicos en Medicina Interna 2017-04-30

<sec> <title>BACKGROUND</title> New technologies can promote knowledge of HIV infection among patients suffering from this disease. Older with represent an increasingly large group that could benefit the use specific apps. </sec> <title>OBJECTIVE</title> The aim study was to observe acceptability and a mobile app on in at least 60 years old offer them possibility anonymously establishing contact their peers. <title>METHODS</title> A series clinical psychosocial parameters were studied 30...

10.2196/preprints.9904 preprint EN 2018-01-29
Coming Soon ...